MALDI imaging mass spectrometry reveals COX7A2, TAGLN2 and S100-A10 as novel prognostic markers in Barrett's adenocarcinoma

Journal of Proteomics

Volumn 75, Issue 15, 2012, Pages 4693-4704

  Elsner, Mareike ^a   Rauser, Sandra ^a   Maier, Stefan ^a   Schöne, Cédrik ^a   Balluff, Benjamin ^a,b   Meding, Stephan ^a   Jung, Gerhard ^a   Nipp, Martin ^a   Sarioglu, Hakan ^a   Maccarrone, Giuseppina ^c   Aichler, Michaela ^a   Feuchtinger, Annette ^a   Langer, Rupert ^d   Jütting, Uta ^a   Feith, Marcus ^b   Küster, Bernhard ^d   Ueffing, Marius ^a,e   Zitzelsberger, Horst ^a   Höfler, Heinz ^a,d   Walch, Axel ^a  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Barrett's adenocarcinoma; Carcinogenesis; COX7A2; MALDI imaging mass spectrometry; S100 A10; TAGLN2

Indexed keywords

CARRIER PROTEINS AND BINDING PROTEINS; COX7A2 PROTEIN; DIAZEPAM BINDING INHIBITOR SPLICE FORM 1A; S100 A10 PROTEIN; THIOREDOXIN; TRANSGELIN 2; TUMOR MARKER; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; BARRETT ADENOCARCINOMA; CANCER PROGNOSIS; CLINICAL ARTICLE; ESOPHAGEAL ADENOCARCINOMA; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS;

ADENOCARCINOMA; ANNEXIN A2; ELECTRON TRANSPORT COMPLEX IV; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICROFILAMENT PROTEINS; MUSCLE PROTEINS; NEOPLASM INVASIVENESS; PROGNOSIS; PROTEOMICS; S100 PROTEINS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 84864092193     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2012.02.012     Document Type: Article

References (42)

1. Koppert L.B., Wijnhoven B.P.L., van Dekken H., Tilanus H.W., Dinjens W.N.M. The molecular biology of esophageal adenocarcinoma. J Surg Oncol 2005, 92:169-190.
2. Shaheen N.J., Richter J.E. Barrett's oesophagus. Lancet 2009, 373:850-861.
3. Reid B.J., Li X., Galipeau P.C., Vaughan T.L. Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis. Nat Rev Cancer 2010, 10:87-101.
4. Walch A.K., Zitzelsberger H.F., Bruch J., Keller G., Angermeier D., Aubele M.M., et al. Chromosomal imbalances in Barrett's adenocarcinoma and the metaplasia-dysplasia-carcinoma sequence. Am J Pathol 2000, 156:555-566.
5. Wild C.P., Hardie L.J. Reflux, Barrett's oesophagus and adenocarcinoma: burning questions. Nat Rev Cancer 2003, 3:676-684.
6. Heath E.I., Canto M.I., Piantadosi S., Montgomery E., Weinstein W.M., Herman J.G., et al. Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial. J Natl Cancer Inst 2007, 99:545-557.
7. Balluff B., Schöne C., Höfler H., Walch A. MALDI imaging mass spectrometry for direct tissue analysis: technological advancements and recent applications. Histochem Cell Biol 2011, 136:227-244.
8. Stoeckli M., Chaurand P., Hallahan D.E., Caprioli R.M. Imaging mass spectrometry: a new technology for the analysis of protein expression in mammalian tissues. Nat Med 2001, 7:493-496.
9. Sobin L.H., Gospodarowicz M.K., Wittekind C. TNM Classification of Malignant Tumours 2009, Whiley-Liss, New York. 7 ed.
10. Gloeckner C.J., Boldt K., Ueffing M. Strep/FLAG tandem affinity purification (SF-TAP) to study protein interactions. Current Protocols in Protein Science 2001, John Wiley & Sons, Inc.
11. Nesvizhskii A.I., Keller A., Kolker E., Aebersold R. A statistical model for identifying proteins by tandem mass spectrometry. Anal Chem 2003, 75:4646-4658.
12. Schwartz S.A., Weil R.J., Thompson R.C., Shyr Y., Moore J.H., Toms S.A., et al. Proteomic-based prognosis of brain tumor patients using direct-tissue matrix-assisted laser desorption ionization mass spectrometry. Cancer Res 2005, 65:7674-7681.
13. Vimalachandran D., Greenhalf W., Thompson C., Lüttges J., Prime W., Campbell F., et al. High nuclear S100A6 (Calcyclin) is significantly associated with poor survival in pancreatic cancer patients. Cancer Res 2005, 65:3218-3225.
14. Wulfkuhle J.D., Sgroi D.C., Krutzsch H., McLean K., McGarvey K., Knowlton M., et al. Proteomics of human breast ductal carcinoma in situ. Cancer Res 2002, 62:6740-6749.
15. Balluff B., Rauser S., Meding S., Elsner M., Schöne C., Feuchtinger A., et al. MALDI Imaging Identifies Prognostic Seven-Protein Signature of Novel Tissue Markers in Intestinal-Type Gastric Cancer. Am J Pathol 2011, 179(6):2720-2729.
16. Shields J.M., Rogers-Graham K., Der C.J. Loss of transgelin in breast and colon tumors and in RIE-1 cells by ras deregulation of gene expression through raf-independent pathways. J Biol Chem 2002, 277:9790-9799.
17. Zhao L., Wang H., Deng Y.-J., Wang S., Liu C., Jin H., et al. Transgelin as a suppressor is associated with poor prognosis in colorectal carcinoma patients. Mod Pathol 2009, 22:786-796.
18. Yang Z., Chang Y.-J., Miyamoto H., Ni J., Niu Y., Chen Z., et al. Transgelin functions as a suppressor via inhibition of ARA54-enhanced androgen receptor transactivation and prostate cancer cell growth. Mol Endocrinol 2007, 21:343-358.
19. Mallick P., Kuster B. Proteomics: a pragmatic perspective. Nat Biotechnol 2010, 28:695-709.
20. Rauser S., Deininger S.-O., Suckau D., Höfler H., Walch A. Approaching MALDI molecular imaging for clinical proteomic research: current state and fields of application. Expert Rev Proteomics 2010, 7:927-941.
21. Dano K., Behrendt N., Hoyer-Hansen G., Johnsen M., Lund L.R., Ploug M., et al. Plasminogen activation and cancer. Thromb Haemost 2005, 93:676-681.
22. O'Connell P.A., Surette A.P., Liwski R.S., Svenningsson P., Waisman D.M. S100A10 regulates plasminogen-dependent macrophage invasion. Blood 2010, 116:1136-1146.
23. Salmela M.T., Karjalainen-Lindsberg M.L., Puolakkainen P., Saarialho-Kere U. Upregulation and differential expression of matrilysin (MMP-7) and metalloelastase (MMP-12) and their inhibitors TIMP-1 and TIMP-3 in Barrett's oesophageal adenocarcinoma. Br J Cancer 2001, 85:383-392.
24. Phipps K.D., Surette A.P., O'Connell P.A., Waisman D.M. Plasminogen receptor S100A10 is essential for the migration of tumor-promoting macrophages into tumor sites. Cancer Res 2011, 71:6676-6683.
25. El-Rifai W., Moskaluk C.A., Abdrabbo M.K., Harper J., Yoshida C., Riggins G.J., et al. Gastric cancers overexpress S100A calcium-binding proteins. Cancer Res 2002, 62:6823-6826.
26. Domoto T., Miyama Y., Suzuki H., Teratani T., Arai K., Sugiyama T., et al. Evaluation of S100A10, annexin II and B-FABP expression as markers for renal cell carcinoma. Cancer Sci 2007, 98:77-82.
27. Cross S.S., Hamdy F.C., Deloulme J.C., Rehman I. Expression of S100 proteins in normal human tissues and common cancers using tissue microarrays: S100A6, S100A8, S100A9 and S100A11 are all overexpressed in common cancers. Histopathology 2005, 46:256-269.
28. Tan Y., Ma S.-Y., Wang F.-Q., Meng H.-P., Mei C., Liu A., et al. Proteomic-based analysis for identification of potential serum biomarkers in gallbladder cancer. Oncol Rep 2011, 26:853-859.
29. Fornuskova D., Stiburek L., Wenchich L., Vinsova K., Hansikova H., Zeman J. Novel insights into the assembly and function of human nuclear-encoded cytochrome c oxidase subunits 4, 5a, 6a, 7a and 7b. Biochem J 2010, 428:363-374.
30. Galati D., Srinivasan S., Raza H., Prabu S.K., Hardy M., Chandran K., et al. Role of nuclear-encoded subunit Vb in the assembly and stability of cytochrome c oxidase complex: implications in mitochondrial dysfunction and ROS production. Biochem J 2009, 420:439-449.
31. Warburg O. On the origin of cancer cells. Science 1956, 123:309-314.
32. Carew J.S., Huang P. Mitochondrial defects in cancer. Mol Cancer 2002, 1:9.
33. Godinot C., de Laplanche E., Hervouet E., Simonnet H. Actuality of Warburg's views in our understanding of renal cancer metabolism. J Bioenerg Biomembr 2007, 39:235-241.
34. Hervouet E., Demont J., Pecina P., Vojtiskova A., Houstek J., Simonnet H., et al. A new role for the von Hippel-Lindau tumor suppressor protein: stimulation of mitochondrial oxidative phosphorylation complex biogenesis. Carcinogenesis 2005, 26:531-539.
35. Simonnet H., Alazard N., Pfeiffer K., Gallou C., Béroud C., Demont J., et al. Low mitochondrial respiratory chain content correlates with tumor aggressiveness in renal cell carcinoma. Carcinogenesis 2002, 23:759-768.
36. Oppenheimer S.R., Mi D., Sanders M.E., Caprioli R.M. Molecular Analysis of Tumor Margins by MALDI Mass Spectrometry in Renal Carcinoma. J Proteome Res 2010, 9:2182-2190.
37. J-h Rho, Roehrl M.H.A., Wang J.Y. Tissue Proteomics Reveals Differential and Compartment-Specific Expression of the Homologs Transgelin and Transgelin-2 in Lung Adenocarcinoma and Its Stroma. J Proteome Res 2009, 8:5610-5618.
38. Shapland C., Hsuan J.J., Totty N.F., Lawson D. Purification and properties of transgelin: a transformation and shape change sensitive actin-gelling protein. J Cell Biol 1993, 121:1065-1073.
39. Lawson D., Harrison M., Shapland C. Fibroblast transgelin and smooth muscle SM22 alpha are the same protein, the expression of which is down-regulated in many cell lines. Cell Motil Cytoskeleton 1997, 38:250-257.
40. LaTulippe E., Satagopan J., Smith A., Scher H., Scardino P., Reuter V., et al. Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res 2002, 62:4499-4506.
41. Nair R.R., Solway J., Boyd D.D. Expression cloning identifies transgelin (SM22) as a novel repressor of 92-kDa type IV collagenase (MMP-9) expression. J Biol Chem 2006, 281:26424-26436.
42. Assinder S.J., Stanton J.-A.L., Prasad P.D. Transgelin: An actin-binding protein and tumour suppressor. Int J Biochem Cell Biol 2009, 41:482-486.